Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Alector develops medicines that use the body's immune system to fight brain diseases like Alzheimer's and Parkinson's.
Alector is a biotech company trying to solve one of medicine's hardest problems: brain diseases that slowly rob people of their memory and movement. Its focus is on Alzheimer's and Parkinson's, plus a handful of rarer brain disorders. The core idea is unusual. Instead of attacking the toxic proteins that build up in diseased brains directly, Alector writes drugs that wake up the brain's own cleanup crew — immune cells called microglia — and push them to clear the mess.
The science hangs on a simple observation: microglia have built-in "off switches" that keep them from going berserk. Alector's lead drug, an antibody called AL001, blocks one of those switches, which lets the immune cells stay active and do their job. The same approach is being tested in front-line Alzheimer's and Parkinson's programs. Getting any brain drug to work is brutally hard — the brain is walled off from most medicines, trials are long, and failure is the norm in this field. That risk is the whole story with Alector. Alector has no approved product and no sales, so its money comes from partners and investors. Its biggest backer is AbbVie, which has paid it hundreds of millions of dollars to share the cost and the upside of the Alzheimer's and Parkinson's programs. Patients pay nothing yet; the bet is that someday insurers and health systems will pay for a drug that actually slows these diseases.
The company has had a rough stretch. A key Parkinson's trial was stopped early, shares have fallen hard, and the company has cut staff to stretch its cash. On the plus side, one of its rare-disease programs has shown promising early results. Alector sits in that classic biotech spot: burning cash today on a high-risk scientific gamble that could pay off enormously — or not at all.
Saved answer · last researched 16 Nov 2026